Scheimpflug imaging is effective for detecting narrow angles

Article

Data recently published in Eye has demonstrated that anterior chamber volume (ACV) measurements taken with Scheimpflug imaging is better for detecting narrow angles than spectral domain anterior segment optical coherence tomography (SD-ASOCT).

Data recently published in Eye has demonstrated that anterior chamber volume (ACV) measurements taken with Scheimpflug imaging is better for detecting narrow angles than spectral domain anterior segment optical coherence tomography (SD-ASOCT).

A team led by Dr D.S. Grewal, Department of Ophthalmology, Northwestern University of Feinberg School of Medicine, Chicago, USA, conducted a prospective, cross-sectional, observational study on 265 eyes of 265 patients. Each patient underwent sequential Schiempflug, SD-ASOCT imaging and gonioscopy. The outcome measures included area under receiver operating characteristic curve (AUC), sensitivity, specificity, and likelihood ratios (LRs). These were used to measure the performance of ACV, anterior chamber depth (ACD), angle opening distance (AOD500), and trabecular-iris space area (TISA500) in detecting narrow angles.

Of the eyes studied, 28 eyes were identified as narrow angles on gonioscopy. When detecting narrow angles ACD and ACV performed similarly to each other and significantly better than the nasal and temporal for both AOD500 and TISA500.

The findings demonstrated overall sensitivity and specificity for detecting narrow angles of ACV was 90% and 88%, respectively. The positive and negative LRs were 8.63 and 0.11, respectively. The use of Scheimpflug imaging to perform ACV measurements is more successful than AOD500 and TISA500 for the detection of narrow angles.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.